Kyverna Therapeutics (KYTX) Operating Leases (2023 - 2026)

Kyverna Therapeutics' Operating Leases history runs 4 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• Quarterly Operating Leases rose 112.13% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (up 112.13% YoY) and the FY2025 annual result came in at $320000.0, down 92.31% from the prior year.
• Operating Leases was $7.0 million for Q1 2026 at Kyverna Therapeutics, up from $320000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $7.0 million in Q1 2026 and bottomed at $320000.0 in Q4 2025.
• A 4-year average of $4.1 million and a median of $4.6 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2025 — Operating Leases slumped 92.31% — and 2026, when it jumped 112.13%.
• Kyverna Therapeutics' Operating Leases stood at $5.2 million in 2023, then fell by 20.58% to $4.2 million in 2024, then slumped by 92.31% to $320000.0 in 2025, then soared by 2074.38% to $7.0 million in 2026.
• Business Quant data shows KYTX's Operating Leases at $7.0 million in Q1 2026, $320000.0 in Q4 2025, and $1.3 million in Q3 2025.